Diadema Partners LP Sells 40,002 Shares of Viridian Therapeutics, Inc. $VRDN

Diadema Partners LP lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 24.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 122,061 shares of the company’s stock after selling 40,002 shares during the period. Diadema Partners LP’s holdings in Viridian Therapeutics were worth $1,706,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of VRDN. Y Intercept Hong Kong Ltd bought a new stake in Viridian Therapeutics during the second quarter valued at $170,000. Creative Planning acquired a new position in shares of Viridian Therapeutics in the 2nd quarter valued at about $179,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at about $180,000. EntryPoint Capital LLC acquired a new stake in Viridian Therapeutics during the first quarter worth approximately $185,000. Finally, Envestnet Asset Management Inc. bought a new stake in Viridian Therapeutics in the second quarter worth approximately $187,000.

Insider Transactions at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc acquired 454,545 shares of the firm’s stock in a transaction on Thursday, October 23rd. The stock was purchased at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the acquisition, the director owned 3,914,458 shares of the company’s stock, valued at approximately $86,118,076. This trade represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.65% of the company’s stock.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $31.80 on Wednesday. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07. The firm has a fifty day simple moving average of $26.11 and a two-hundred day simple moving average of $20.24. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $33.34. The firm has a market capitalization of $3.04 billion, a PE ratio of -10.53 and a beta of 0.86.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. The firm had revenue of $70.57 million for the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. Viridian Therapeutics’s revenue for the quarter was up 81993.0% compared to the same quarter last year. Analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. BTIG Research restated a “buy” rating and set a $61.00 price target on shares of Viridian Therapeutics in a report on Tuesday, November 4th. The Goldman Sachs Group reiterated a “buy” rating and set a $40.00 target price on shares of Viridian Therapeutics in a research report on Thursday, November 6th. William Blair began coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, October 8th. Finally, Truist Financial set a $41.00 price objective on shares of Viridian Therapeutics in a research report on Monday, November 24th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $40.55.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.